Paraoxonase 1 Activity Assay Kit (ab241044)
Key features and details
- Detection method: Fluorescent
- Platform: Microplate reader
- Sample type: Plasma, Serum
Overview
-
Product name
Paraoxonase 1 Activity Assay Kit
See all PON1 kits -
Detection method
Fluorescent -
Sample type
Serum, Plasma -
Product overview
Paraoxonase 1 Activity Assay Kit (ab241044) enables rapid measurement of Paraoxonase 1 (PON1) activity, utilizing a fluorogenic substrate that is converted into a highly fluorescent product (Ex/Em = 368/460 nm). This ensures dramatically greater sensitivity than UV or colorimetric assays and eliminates the need for dangerous toxic substrates. A selective PON1 inhibitor is provided for verification of PON1 specific activity. The assay is simple to perform, high-throughput adaptable and can detect a minimum of 2.0 μU paraoxonase activity with a sample volume of 5 μL.
-
Platform
Microplate reader
Properties
-
Storage instructions
Store at -20°C. Please refer to protocols. -
Components 100 tests Fluorescence Standard 1 vial Paraoxonase Assay Buffer 1 x 50ml Paraoxonase Positive Control 1 vial PON1 Inhibitor (2-hydroxyquinoline) 1 vial PON1 Substrate 1 vial -
Research areas
-
Function
Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation. -
Tissue specificity
Plasma, associated with HDL (at protein level). Expressed in liver, but not in heart, brain, placenta, lung, skeletal muscle, kidney or pancreas. -
Involvement in disease
Genetic variation in PON1 is associated with susceptibility to microvascular complications of diabetes type 5 (MVCD5) [MIM:612633]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Note=Homozygosity for the Leu-54 allele is strongly associated with the development of retinal disease in diabetic patients. -
Sequence similarities
Belongs to the paraoxonase family. -
Post-translational
modificationsGlycosylated.
The signal sequence is not cleaved.
Present in two forms, form B contains a disulfide bond, form A does not. -
Cellular localization
Secreted > extracellular space. - Information by UniProt
-
Alternative names
- A esterase 1
- A-esterase 1
- Aromatic esterase 1
see all
Images
-
Standard curve of PON1.Standard curve of PON1 Substrate metabolite fluorescence. One mole of fluorescence standard corresponds to the metabolism of one mole of PON1 Substrate.
-
Reaction kinetics of PON1 Substrate metabolism.Reaction kinetics of PON1 Substrate metabolism in donor-pooled human serum (5 µL), donor-pooled human plasma (5 µL) and rabbit serum (2.5 µL) in the presence and absence of 200 µM of the selective PON1 inhibitor 2- hydroxyquinoline (no inhibitor conditions contained 0.4% DMSO as a solvent control).
-
Quantification of PON1 activity in serum/plasma samples.Quantification of PON1 activity in serum/plasma samples (mean ± SEM of four independent replicates). Assays were performed according to the kit protocol.